
    
      This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent
      or persistent CTCL. The study consists of an initial Lead-in part (to select recommended dose
      of E7777 for Main part), followed by the Main part (to test efficacy). Lead in part is
      complete and main study is ongoing. Participants will move through three phases while on
      study: Pretreatment Phase, Treatment Phase, and Extension Phase and a Follow-up Period.
    
  